1-19 of 19
Matteo S. Carlino
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Hansol Lee, Angela L. Ferguson, Camelia Quek, Ismael A. Vergara, Ines Pires daSilva, Ruth Allen, Tuba Nur Gide, Jordan W. Conway, Lambros T. Koufariotis, Nicholas K. Hayward, Nicola Waddell, Matteo S. Carlino, Alexander M. Menzies, Robyn P.M. Saw, Elena Shklovskaya, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long, Umaimainthan Palendira, James S. Wilmott
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2513–2524.
https://doi.org/10.1158/1078-0432.CCR-22-2657
Published: 05 July 2023
View article titled, Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Open the PDF for Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3002–3010.
https://doi.org/10.1158/1078-0432.CCR-21-3872
Published: 15 July 2022
View article titled, Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma
Open the PDF for Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View article titled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Journal Articles

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q. Wong, Michelle R. Pereira, Ashleigh C. McEvoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A. Khattak, Tarek M. Meniawy, Sarah-Jane Dawson, Shahneen Sandhu, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Benhur Amanuel, Michael Millward, Melanie R. Ziman, Helen Rizos, Elin S. Gray
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5926–5933.
https://doi.org/10.1158/1078-0432.CCR-20-2251
Published: 13 November 2020
View article titled, Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Open the PDF for Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View article titled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors

Ryan J. Sullivan, Jeffrey Weber, Sapna Patel, Reinhard Dummer, Matteo S. Carlino, Daniel S.W. Tan, Celeste Lebbé, Salvatore Siena, Elena Elez, Lance Wollenberg, Michael D. Pickard, Victor Sandor, Paolo A. Ascierto
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5102–5112.
https://doi.org/10.1158/1078-0432.CCR-19-3550
Published: 01 October 2020
View article titled, A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <em>BRAF<sup>V600E/K</sup></em>-mutant Solid Tumors
Open the PDF for A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <em>BRAF<sup>V600E/K</sup></em>-mutant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4454–4459.
https://doi.org/10.1158/1078-0432.CCR-20-0621
Published: 01 September 2020
View article titled, Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Open the PDF for Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers in another window
Includes: Supplementary data
Journal Articles

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

Jenny H. Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppler, Russell J. Diefenbach, Sarah-Jane Dawson, Richard F. Kefford, Michael J. Millward, Zeyad Al-Ogaili, Thien Tra, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4064–4071.
https://doi.org/10.1158/1078-0432.CCR-19-3926
Published: 03 August 2020
View article titled, Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Open the PDF for Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Su Y. Lim, Jenny H. Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Y.H. Yang, Shila Ghazanfar, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1557–1563.
https://doi.org/10.1158/1078-0432.CCR-18-2795
Published: 01 March 2019
View article titled, Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Open the PDF for Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, Alexander M. Menzies
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1272–1279.
https://doi.org/10.1158/1078-0432.CCR-18-1680
Published: 15 February 2019
View article titled, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma
Open the PDF for Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Curtis H. Kugel, III, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al-Rohil, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell Fane, Michael J. Allegrezza, Nikolaos Svoronos, Vinit Kumar, Daniel Y. Wang, Rajasekharan Somasundaram, Siwen Hu-Lieskovan, Alpaslan Ozgun, Meenhard Herlyn, Jose R. Conejo-Garcia, Dmitry Gabrilovich, Erica L. Stone, Theodore S. Nowicki, Jeffrey Sosman, Rajat Rai, Matteo S. Carlino, Georgina V. Long, Richard Marais, Antoni Ribas, Zeynep Eroglu, Michael A. Davies, Bastian Schilling, Dirk Schadendorf, Wei Xu, Ravi K. Amaravadi, Alexander M. Menzies, Jennifer L. McQuade, Douglas B. Johnson, Iman Osman, Ashani T. Weeraratna
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5347–5356.
https://doi.org/10.1158/1078-0432.CCR-18-1116
Published: 01 November 2018
View article titled, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Open the PDF for Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Y. H. Yang, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6054–6061.
https://doi.org/10.1158/1078-0432.CCR-16-1688
Published: 12 October 2017
View article titled, PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Open the PDF for PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam J. Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard F. Kefford, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5024–5033.
https://doi.org/10.1158/1078-0432.CCR-16-0698
Published: 31 August 2017
View article titled, Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Open the PDF for Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma in another window
Includes: Supplementary data
Journal Articles

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Matteo S. Carlino, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 3992–3998.
https://doi.org/10.1158/1078-0432.CCR-15-2944
Published: 14 August 2016
View article titled, Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Open the PDF for Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? in another window
Journal Articles

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

Ravi K. Amaravadi, Kathryn E. Hamilton, Xiaohong Ma, Shengfu Piao, Armando Del Portillo, Katherine L. Nathanson, Matteo S. Carlino, Georgina V. Long, Igor Puzanov, Xiaowei Xu, Jennifer J.D. Morrissette, Kenneth Y. Tsai, Keith T. Flaherty, Jeffrey A. Sosman, Grant R. Goodman, Grant A. McArthur, Anil K. Rustgi, David C. Metz, Lynn M. Schuchter, Paul B. Chapman, Antonia R. Sepulveda
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5215–5221.
https://doi.org/10.1158/1078-0432.CCR-15-0469
Published: 30 November 2015
View article titled, Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Open the PDF for Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors in another window
Includes: Supplementary data
Journal Articles

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan M. Nagrial, Richard A. Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 98–105.
https://doi.org/10.1158/1078-0432.CCR-14-0759
Published: 05 January 2015
View article titled, Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Open the PDF for Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients in another window
Includes: Supplementary data
Journal Articles

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie Howle, Robyn Saw, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (7): 1965–1977.
https://doi.org/10.1158/1078-0432.CCR-13-3122
Published: 31 March 2014
View article titled, BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Open the PDF for BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact in another window
Includes: Supplementary data
Journal Articles

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

Alexander M. Menzies, Lauren E. Haydu, Lydia Visintin, Matteo S. Carlino, Julie R. Howle, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3242–3249.
https://doi.org/10.1158/1078-0432.CCR-12-0052
Published: 14 June 2012
View article titled, Distinguishing Clinicopathologic Features of Patients with V600E and V600K <em>BRAF</em>-Mutant Metastatic Melanoma
Open the PDF for Distinguishing Clinicopathologic Features of Patients with V600E and V600K <em>BRAF</em>-Mutant Metastatic Melanoma in another window
Includes: Supplementary data